MRUS News

Halper Sadeh LLC Encourages CADE, THS, CMA, MRUS Shareholders to Contact the Firm to Discuss Their Rights

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights

Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker

Merus kondigt de selectie aan van het abstract: Petosemtamab in Metastatic Colorectal Cancer (petosemtamab in gemetastaseerde colorectale kanker) voor mondelinge presentatie in de plenaire sessie op de AACR-NCI-EORTC International Conference on Molecular

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics